Prospective Study to Investigate the Long-Term Outcomes in Japanese Patients with Early Alzheimer's Disease who are treated with Lecanemab in the Real World Clinical Setting

An Observational, Multicenter, Prospective Study to Investigate the Long-Term Outcomes in Japanese Patients with Early Alzheimer's Disease who are treated with Lecanemab in the Real World Clinical Setting (VISION AD-JP)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031260237

Enrollment

750

Registered

2026-06-19

Start date

2026-06-30

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Determined to be appropriate as a treatment candidate based on the indication for lecanemab. A study partner who will provide written consent in a separate document has been identified. Written consent has been obtained for the use of medical information in this study.

Exclusion criteria

Exclusion criteria: Participating in an interventional clinical study (e.g., a clinical trial or specified clinical research). A history of exposure to lecanemab. Use of lecanemab is contraindicated.

Design outcomes

Primary

Measure	Time frame
time to progression to the next stage of AD as measured by the global Clinical Dementia Rating (CDR)	—

Secondary

Measure	Time frame
Change from baseline in MMSE at each evaluation time point Change from baseline in QDRS at each evaluation time point Change from baseline in digital biomarkers at each evaluation time point	—

Contacts

Public ContactYosuke Nakamura

Eisai Co., Ltd.

eisai-medicalHQ@hhc.eisai.co.jp+81-3-3817-3700

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026